Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroDose Therapeutx has completed an open-label, active-controlled, crossover, safety Phase I study evaluating pharmacokinetics of atropine dry powder inhalation in 17 adult healthy subjects.
Subscribe to our email newsletter
The study has been conducted by the Microdose’s collaborators at the University of Pittsburgh with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).
The Phase I trial compared multiple inhalations of an atropine dry powder with one dose of a commercially marketed atropine intramuscular (IM) injection.
MicroDose Product Commercialization Group senior director Robert Cook said follow-up trials will further demonstrate their ability to achieve high atropine bioavailability from the MicroDose inhaler (85%, relative to IM atropine) to attain both local and systemic signs of atropinization.